P1189: ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY

P1189: ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY

Bibliographic Details
Main Authors:	Ronakrit Thanhakun, Chantiya Chanswangphuwana, Chantana Polprasert, Sunisa Kongkiatkamon, Panisinee Lawasut, Udomsak Bunworasate, Kitsada Wudhikarn
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971652.52235.b1

Similar Items

P1238: GERMLINE HAVCR2 MUTATIONS AND THEIR RELATION TO THE CLINICAL SPECTRUM OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA AND HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: RESULTS FROM A MULTICENTER STUDY
by: Chantana Polprasert, et al.
Published: (2023-08-01)

Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation
by: Thiti Asawapanumas, et al.
Published: (2022-01-01)

Germline <i>HAVCR2</i> mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta-analysis
by: Chatphatai Moonla, et al.
Published: (2023-04-01)

Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients
by: Naritsara Cherdchoo, et al.
Published: (2023-12-01)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients.
by: Kamalas Amnuay, et al.
Published: (2019-09-01)

The Massacres of the Jews under Richard I (A.D. 1189–1190)
by: Ted Booth
Published: (2021-09-01)

Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy
by: Nai-Wen Kang, et al.
Published: (2017-12-01)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
by: Marta Rodríguez, et al.
Published: (2022-08-01)

The history of building regulation in London 1189-1972 with an account of the District Surveyors' Association/
by: 373284 Knowles, C. C., et al.
Published: (1972)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
by: Jéssica Santos Cunha, et al.
Published: (2021-03-01)

The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study
by: Pravinwan Thungthong, et al.
Published: (2023-03-01)

The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma
by: Man Sun, et al.
Published: (2024-12-01)

Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
by: Teerachat Punnachet, et al.
Published: (2024-10-01)

Prediction of immunochemotherapy response for diffuse large B‐cell lymphoma using artificial intelligence digital pathology
by: Jeong Hoon Lee, et al.
Published: (2024-05-01)

Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG
by: Smith Kungwankiattichai, et al.
Published: (2023-12-01)

P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
by: A. McMillan, et al.
Published: (2022-06-01)

Utilizing Clinical Transformation Criteria for Prognostic Stratification in Follicular Lymphoma Prior to Initial Immunochemotherapy
by: Yoshikazu Hori, et al.
Published: (2024-10-01)

Treatment of B-cells non-Hodgkin lymphomas with combined immunochemotherapy: ability to treatment optimization
by: N. V. Smirnova, et al.
Published: (2015-12-01)

Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy
by: M. Egyed, et al.
Published: (2007-02-01)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
by: Erik Gaitzsch, et al.
Published: (2021-07-01)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
by: Christine Schmitz, et al.
Published: (2020-11-01)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
by: Sang Eun Yoon, et al.
Published: (2023-11-01)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
by: Tawatchai Suwanban, et al.
Published: (2023-08-01)

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
by: Zachary D. Epstein-Peterson, et al.
Published: (2023-08-01)

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
by: Joanna Romejko-Jarosinska, et al.
Published: (2022-06-01)

Objectification of the method for glomerular filtration rate assessing in patients with diffuse large B-cell lymphoma during induction immunochemotherapy
by: A. S. Nozdricheva, et al.
Published: (2024-04-01)

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
by: Alexandra Valera, et al.
Published: (2013-10-01)

A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large‐B cell lymphoma during treatment with immunochemotherapy
by: Limei Zhang, et al.
Published: (2023-03-01)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
by: Michael Herold, et al.
Published: (2022-03-01)

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
by: Yucai Wang, et al.
Published: (2022-01-01)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
by: Ganesh Yadagiri, et al.
Published: (2023-05-01)

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
by: Nyman, H, et al.
Published: (2009)

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
by: Nyman, H, et al.
Published: (2008)

Clinical Characteristics and Risk of Relapse for Patients with Stage I–II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy
by: S. Mercadal, et al.
Published: (2013-11-01)

Treatment of a Frail Older Patient with Diffuse Large B-Cell Lymphoma on Maintenance Dialysis: Attenuated Immunochemotherapy and Adapted Care Plan
by: Luciola de Barros Pontes, et al.
Published: (2013-04-01)

T-PLL Presenting with an Indolent Course
by: Arsa Thammahong, et al.
Published: (2024-01-01)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
by: Kathrine T. Isaksen, et al.
Published: (2023-03-01)

Changes in glucose metabolism of the brain after immunochemotherapy in patients with diffuse large B-Cell lymphoma on fluorodeoxyglucose positron emission tomography/computed tomography
by: Ogün Bulbul, et al.
Published: (2023-01-01)

<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
by: Zachary D. Epstein-Peterson, et al.
Published: (2024-08-01)

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
by: Josep-Maria Ribera, et al.
Published: (2023-08-01)